FluoroPharma nets 18F-FDG patent for imaging cardiovascular plaque
The U.S. Patent and Trademark Office has issued FluoroPharma, a developer of PET molecular imaging agents, a patent that covers imaging cardiovascular plaque formation using 18F-FDG in PET imaging.

The Boston-based company said its U.S. Patent No. 7,438,891, exclusively licensed from the Massachusetts General Hospital (MGH), has additional patent claims that cover imaging of atherosclerotic plaque inflammation and rupture.

“In vivo noninvasive clinical studies to measure carotid plaque inflammation show that 18F-FDG PET imaging can identify a subset of patients with carotid atherosclerosis that may benefit from intensified medical therapy or carotid artery intervention to prevent stroke,” said Tom Brady, director of nuclear medicine and molecular imaging division at MGH in Boston.